PHILADELPHIA – The American Society of clinical Oncology has named University of Pennsylvania cancer and HIV gene therapy pioneer Carl June, MD
, as the 2017 winner of the David A. Karnofsky Memorial Award. The honor goes to an oncologist who has made outstanding contributions to cancer research, diagnosis, and treatment. In addition to receiving the award, June will give the Karnofsky Lecture on Saturday, June 3,
during the American Society of Clinical Oncology Annual meeting in Chicago.
June is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine at Penn’s Perelman School of Medicine, the director of the Center for Cellular Immunotherapy in the Abramson Cancer Center, and the director of the Parker Institute for Cancer Immunotherapy at Penn. He is being recognized with the Karnofsky Award for his pioneering work developing a personalized cellular therapy for cancer known as chimeric antigen receptor (CAR) T cell therapy. Clinical trials of this approach began at Penn in 2010, and two of the first three patients to receive the therapy, for chronic lymphocytic leukemia (CLL) remain in remission nearly seven years later. Studies of the approach were later launched for acute lymphoblastic leukemia in both pediatric and adult patients who had stopped responding to conventional treatments, with results revealing that as many of 90 percent of patients who received the therapy went into remission. Additional studies using CAR T cell therapy are underway at Penn for non-Hodgkin’s lymphoma, multiple myeloma, glioblastoma, pancreatic and ovarian cancers, mesothelioma, melanoma, and breast cancer.
June has published more than 350 manuscripts and has received numerous prizes and honors, including election of the Institute of Medicine in 2012, the Paul Ehrlich and Ludwig Darmstaedter Prize, the William b. Coley award, the Karl Landsteiner Memorial Award from the AARB, the Richard V. Smalley Memorial Award from the Society for Immunotherapy of Cancer, the Philadelphia Award, the Hamdan Award for Medical Research Excellence, and the Novartis Immunology Award for Cancer Cell Therapy Development. He was elected to the American Academy of Arts and Sciences in 2014. In April, he was named a fellow of the American Association for Cancer Research Academy.
June is a graduate of the U.S. Naval Academy, as well as Baylor College of Medicine in Houston. He received graduate training in Immunology and Malaria at the World Health Organization in Geneva, Switzerland, and post-doctoral training in transplantation biology at the Fred Hutchinson Cancer Research Center.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.